Entropy Neurodynamics Completes First-Cohort Dosing in Binge Eating Disorder Trial
MT Newswires Live
Jun 02
Entropy Neurodynamics (ASX:ENP) said it completed dosing for all six participants in the first cohort of its phase two clinical trial of TRP-8803 for the treatment of patients with binge eating disorder, according to a Tuesday filing with the Australian bourse.
Each participant received two doses of TRP-8803 delivered 14 days apart alongside supportive therapy, per the filing.
Participants in the first cohort received a mid-range therapeutic dose, and the regimen for the second cohort will be decided after a review of outcomes for the first cohort.
"Importantly, dosing in cohort one achieved a controlled and reproducible psychedelic response across all participants," Entropy Neurodynamics said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.